COMMUNIQUÉS West-GlobeNewswire

Financière de Tubize - Approbation du dividende

26/04/2025 - 08:00

Approbation du dividende Information réglementée - 25 avril 2025 L’assemblée générale des actionnaires du 25 avril 2025 a approuvé les comptes annuels relatifs à l’exercice social clôturé le 31 décembre 2024, en ce [...]

Financière de Tubize - Dividend approval

26/04/2025 - 08:00

Dividend confirmation Regulated information - 25 april 2025 The general shareholders meeting of 25 April 2025 has approved the annual accounts as at 31 December 2024, including the distribution of a gross dividend of € [...]

Skye Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

26/04/2025 - 02:06

SAN DIEGO, April 25, 2025 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (Nasdaq: SKYE) (“Skye”), a clinical-stage biopharmaceutical company focused on unlocking new therapeutic pathways for metabolic health, today announced [...]

MoonLake Immunotherapeutics to host a Capital Markets Day on Tuesday, April 29

25/04/2025 - 22:05

MoonLake Immunotherapeutics to host a Capital Markets Day on Tuesday, April 29 Zug, Switzerland, April 25, 2025 – MoonLake Immunotherapeutics (Nasdaq: MLTX), a clinical-stage biotechnology company focused on creating [...]

SRx Health Solutions, Inc. (formerly known as Better Choice Company Inc.) Announces Halo Spin-Out Distribution for Stockholders of Record as of April 23, 2025

25/04/2025 - 22:05

TAMPA, Fla., April 25, 2025 (GLOBE NEWSWIRE) -- SRx Health Solutions, Inc. (formerly known as Better Choice Company Inc.) (NYSE American: BTTR) (the “Company”), a leading global health and wellness company, today [...]

AEON Biopharma Announces NYSE American Acceptance of Plan to Regain Listing Compliance

25/04/2025 - 22:05

IRVINE, Calif., April 25, 2025 (GLOBE NEWSWIRE) -- AEON Biopharma, Inc. (“AEON” or the “Company”) (NYSE: AEON), a clinical-stage biopharmaceutical company focused on developing a botulinum toxin complex for the [...]

Prelude Announces Presentations at 2025 AACR Annual Meeting

25/04/2025 - 22:05

Preclinical data elucidating the mechanism of action of PRT3789, Prelude’s first-in-class, highly selective SMARCA2 degrader currently in early clinical development Highlights from Prelude’s efforts to discover and [...]

Myriad Genetics Highlights MRD Clinical Validity Data at American Association for Cancer Research Annual Meeting

25/04/2025 - 22:05

Podium presentation showcases the clinical application of Precise™ MRD SALT LAKE CITY, April 25, 2025 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc . (NASDAQ: MYGN), a leader in molecular diagnostic testing and precision [...]

New Data at AACR Annual Meeting Highlights Use of DecisionDx®-Melanoma to Identify Early-Stage Melanoma Patients at High Risk of Distant Metastasis

25/04/2025 - 22:15

FRIENDSWOOD, Texas, April 25, 2025 (GLOBE NEWSWIRE) -- Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, will share new research intended to improve [...]

Rezolute, Inc. Announces Closing of Underwritten Offering

25/04/2025 - 22:30

NEW YORK, April 25, 2025 (GLOBE NEWSWIRE) -- Rezolute, Inc. (Nasdaq: RZLT) (“Rezolute” or the “Company”), a late-stage biopharmaceutical company committed to developing novel, transformative therapies for serious rare [...]

Celularity Receives Nasdaq Notice Regarding Non-Payment of Nasdaq Fees

25/04/2025 - 23:30

FLORHAM PARK, N.J., April 25, 2025 (GLOBE NEWSWIRE) -- Celularity Inc. (Nasdaq: CELU) (“Celularity” or the “Company”), a cellular and regenerative medicine company, today announced that Nasdaq has notified the Company [...]

Starton Therapeutics Presents Positive Data from Phase 1b Study Evaluating STAR-LLD for the Treatment of Relapsed/Refractory Multiple Myeloma at the American Association for Cancer Research (AACR) Annual Meeting 2025

25/04/2025 - 19:10

PARAMUS, N.J., April 25, 2025 (GLOBE NEWSWIRE) -- Starton Therapeutics Inc. (“Starton”), a clinical-stage biotechnology company transforming standard-of-care therapies with proprietary dermal technologies, announced [...]

ALX Oncology Announces Encouraging Final Results from Phase 1 Trial Evaluating Evorpacept in Combination with Standard-of-Care Treatment in Patients with B-cell Non-Hodgkin Lymphoma

25/04/2025 - 19:10

- Data to be presented at AACR 2025 Annual Meeting suggest the combination of ALX Oncology’s investigational CD47-blocker, evorpacept, plus rituximab and lenalidomide (R 2 ) was well-tolerated and demonstrated promising [...]

Pyxis Oncology Presents Promising Preclinical Results Providing Proof of Mechanism of Micvotabart Pelidotin, the First-in-Concept Extracellular-Targeting ADC

25/04/2025 - 19:17

Gene signatures associated with increased efficacy of micvotabart pelidotin (MICVO) due to greater linker cleavage were identified based on differential gene expression analysis of PDX responders/non-responders Mouse [...]

Tevogen Bio Announces 2025 Annual Meeting

25/04/2025 - 20:33

WARREN, N.J., April 25, 2025 (GLOBE NEWSWIRE) -- Tevogen Bio Holdings Inc. (“Tevogen Bio” or “Company”) (Nasdaq: TVGN ) today announced that the Company will hold its 2025 annual meeting of stockholders (the “Annual [...]

Clenbuterol Bodybuilding (Clen) Pills, Clenbuterol Dosage, Clenbuterol, Benefits, Clenbuterol Side Effects, Clenbuterol Cycles, Where to buy Clenbuterol tablet buy, ambroxol, lavizoo (CrazyBulk)

25/04/2025 - 21:18

New York City, April 25, 2025 (GLOBE NEWSWIRE) -- Why Do People Look for Weight Loss Pills? Many people want a leaner body and look for pills to help them achieve this. One such pill is Clenbuterol , which is often used [...]

Spanios and White Lion Capital LLC Announce Strategic Partnership to Accelerate Drug Development

25/04/2025 - 21:26

HOUSTON, April 25, 2025 (GLOBE NEWSWIRE) -- Spanios, a leader in human-derived organoid model systems, is pleased to announce a strategic partnership with White Lion Capital LLC. This collaboration empowers biotech and [...]

Oculis Updates Share Capital

25/04/2025 - 22:00

ZUG, Switzerland, April 25, 2025 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS; XICE: OCS) (“Oculis” or the “Company”), a global biopharmaceutical company, has issued registered ordinary shares of the Company, each [...]

CHMP recommends EU approval for Duvyzat to treat Duchenne muscular dystrophy

25/04/2025 - 16:17

Recommendation is based on Phase 3 EPIDYS trial data that demonstrated Duvyzat (givinostat) provides statistically and clinically meaningful treatment benefits in individuals with Duchenne muscular dystrophy (DMD) If [...]